

Dr Ping Pui Wong



Research Interests

My main research areas are in Breast Cancer, Pancreatic Cancer, Cell Signalling, Drug Resistance, Preclinical Imaging, Cancer Immunotherapy, Biomarker studies and Clinical Trials.

My research group focuses on:

- Understanding the molecular mechanisms of drug resistance in cancer treatment
- Investigating the role of Melanoma Associated Antigen (MAGEA) proteins in cancer progression and metastasis
- Identifying potential targets for cancer immunotherapy
- Developing primary cancer models and preclinical models for drug resistant cancer studies
- Developing novel drug resistant biomarkers and clinical trials inspired by laboratory results

I am also responsible for teaching medical students and setting up research collaborations at Nanchang university, China.

Major Funders

- Nanchang joint programme
- Barts and the London Charity
- Cancer Research UK

Contact Details

Email: p.p.wong@qmcr.qmul.ac.uk

Dr Ping Pui Wong



Recent Publications

- Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread. **Wong PP**, Demircioglu F, Ghazaly E, Alrawashdeh W, Stratford MR, Scudamore CL, Cereser B, Crnogorac-Jurcevic T, McDonald S, Elia G, Hagemann T, Kocher HM, Hodivala-Dilke KM. *Cancer Cell* (2015) Jan 12;27(1):123-37.
- Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy. Tavora B, Reynolds LE*, Batista S*, Demircioglu F*, Fernandez I*, Lechertier T*, Lees DM*, **Wong PP***, Alexopoulou A, Elia G, Clear A, Ledoux A, Hunter J, Perkins N, Gribben JG, Hodivala-Dilke KM. *Nature* (2014) Oct 2;514(7520):112-6.
- Identification of MAGEA antigens as causal players in the development of tamoxifen-resistant breast cancer. **Wong PP**, Yeoh CC, Ahmad AS, Chelala C, Gillett C, Speirs V, Jones JL, Hurst HC. *Oncogene* (2014) Sep 11;33(37):4579-88.
- Histone demethylase KDM5B collaborates with TFAP2C and Myc to repress the cell cycle inhibitor p21(cip) (CDKN1A). **Wong PP**, Miranda F, Chan KV, Berlatto C, Hurst HC, Scibetta AG. *Mol Cell Biol* (2012) May;32(9):1633-44.
- Dual association by TFAP2A during activation of the p21cip/CDKN1A promoter. **Wong PP***, Scibetta AG*, Chan KV, Canosa M, Hurst HC. *Cell Cycle* (2010) Nov 15;9(22):4525-32.